Wilson Sonsini - ECP

Life Sciences

Our Industry
Coverage

With one of the largest life sciences practices in the U.S., Wilson Sonsini’s industry legacy dates to the formative years of biotech and medical device. Working closely with scientists and entrepreneurs who grew their companies into thriving businesses, we have worked alongside to support their endeavors from whiteboard to clinical trial and beyond.

Industry Highlights

Celebrating our
founders’ successes

Life Sciences Industry

2013

NanoString Files IPO Worth $54 Million

Molecular Diagnostics

2020

Lumos Pharma Sets Sights on SPAC

Drug Discovery

2020

Oric Pharmaceuticals IPO Raises $120 Million

Drug Discovery

2020

Applied Molecular Transport Closes IPO at $154 Million

Pharmaceuticals

2020

ALX Oncology Prices IPO at $161 Million

Immuno-Oncology

2020

HintMD is Acquired by Revance Therapeutics

Mobile Healthcare Platform

2020

Athira Pharma Closes $204 Million IPO

Drug Discovery

2020

PMV Pharmaceuticals Joins Nasdaq with $211 Million IPO

Drug Discovery

2020

Artelo Biosciences Announces $6.6 Million Public Offering

Cannabinoid-Based Therapies

2020

Seer IPO Raises $175 Million in Nasdaq Debut

Decision / Risk Analysis

Attorneys

focused
on this
industry

See all ECP attorneys

Craig
Sherman

Co-Chair
See all ECP attorneys

recent news

we want to share
with you

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Wilson Sonsini Advises 6 Dimensions and Its Portfolio Ignis Therapeutics on Ignis’ $180 Million Series A Financing and Strategic Licensing Agreement with SKBP

Client Highlights11/14/21
Wilson Sonsini Advises Cambridge Epigenetix on IP Matters Related to $88 Million Series D
See all news
See all news

other industries

we have covered

Copyright © 2021 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.